מאמרים (7 שנים אחרונות)
1. Sharabi-Ronen, Y.; Levinger, S.; Ben-Dahan Lellouche, M.; Albeck, A. Anti-neoplastic Activity of 1,3-Diaza-2-functionalized-adamantan-6-one Compounds Against Melanoma Cells. Med. Chem. 2014, 10, 27-37.
2. Traube, T.; Shokhen, M.; Albeck, A. Application of EMBM for Structure-Based Design of Warheads for Protease Inhibitors. Mol Inf 2014, 33, 36-42.
3. Traube, T.; Shokhen, M.; Albeck, A. A New Method for Filtering of Reactive “Warheads” of Transition-State Analog Protease Inhibitors. Eur J Med Chem 2014, 77C, 134-138.
4. Shokhen, M.; Hirsch, M.; Khazanov, N.; Ozeri, R.; Perlman, N.; Traube, T.; Vijayakumar, S.; Albeck, A. From Catalytic Mechanism to Rational Design of Reversible Covalent Inhibitors of Hydrolases. Isr J Chem 2014, 54, 1137-1151.
5. Gilad, Y.; Firer, M. A.; Rozovsky, A.; Ragozin, E.; Redko, B.; Albeck, A.; Gellerman, G. "Switch off/switch on" regulation of drug cytotoxicity by conjugation to a cell targeting peptide. Eur J Med Chem 2014, 85, 139-146.
6. Rozovsky, A.; Regozin, E.; Oron-Herman, M.; Albeck, A.; Gellerman, G. Synthesis of novel antitumor carbazole-amonafide structural hybrids. Eur J Org Chem 2015, 1811-1818.
7. Zats, G. M.; Kovaliov, M.; Albeck, A.; Shatzmiller, S. Antimicrobial Benzodiazepine-Based Short Cationic Peptidomimetics. J Pept Sci 2015, 21, 512-519.
8. Lapidot, I.; Albeck, A.; Gellerman, G.; Shatzmiller, S.; Grynszpan, F. 1,4-Dihydropyridine Cationic Peptidomimetics with Antibacterial Activity. Int J Pept Res Ther 2015, 21, 243-247.
9. Redko, B.; Ragozin, E.; Bazylevich, A.; Tuchinsky, H.; Albeck, A.; Shekhter Zahavi, T.; Oron-Herman, M.; Kostenich, G.; Gellerman, G. Synthesis, drug release and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety. Biopolimers: Pept Sci 2015, 104, 743-752.
10. Lapidot, I.; Baranes, D.; Pinhasov, A.; Gellerman, G.; Albeck, A.; Grynszpan, F.; Shatzmiller, S. E. alpha-Aminoisobutyric acid leads a fluorescent syn-bimane LASER probe across the blood-brain barrier. Med. Chem. 2016, 12, 48-53.
11. Uritsky, N.; Shokhen, M.; Albeck, A. Stepwise vs. Concerted Mechanism in General Base Catalysis by Serine Proteases. Angew Chem 2016, 55, 1680-1684.
12. Gilad, Y.; Noy, E.; Senderowitz, H.; Albeck, A.; Firer, M. A.; Gellerman, G. Synthesis, biological studies and molecular dynamics of new anticancer RGD-based peptide conjugates for targeted drug delivery. Bioorg Med Chem 2016, 24, 294-303.
13. Gilad, Y.; Noy, E.; Senderowitz, H.; Albeck, A.; Firer, M. A.; Gellerman, G. Dual-drug RGD conjugates provide enhanced cytotoxicity of melanoma and non-small lung cancer cells. Biopolymers: Pept. Sci. 2016, 106, 160-171.
14. Ragozin, E.; Redko, B.; Tuchinsky, E.; Rozovsky, A.; Albeck, A.; Grynszpan, F.; Gellerman, G. Bio-Labile Peptidyl Delivery Systems Towards Sequential Drug Release. Biopolymers: Pept. Sci 2016, 106, 119-132.
15. Gilad, Y.; Waintraub, S.; Albeck, A.; Gellerman, G. Synthesis of novel protected Nα(ω-Drug) amino acid building units for facile preparation of anticancer drug-conjugates. Int J Pept Res Ther 2016, 22, 301-316.
16. Silberman, A.; Kalechman, Y.; Hircsh, S.; Erlich, Z.; Sredni, S.; Albeck, A. Integrin inactivation by organotelluranes: potential role in their anti-metastatic activity. ChemBioChem 2016, 17, 918-927.
17. Levinger, S.; Hirsch, S.; Albeck, A. Lithium Aluminum Hydride Assay Suitable for the Organic Chemistry Laboratory. ChemistrySelect 2016, 4, 756-758.
18. Zer-Aviv, P.; Shubely, M.; Moskovits, Y.; Viskind, O.; Albeck, A.; Vertommen, D.; Ruthstein, S.; Shokhen, M.; Gruzman, A. A new oxopiperazin-based peptidomimetic molecule inhibits prostatic acid phosphatase secretion and induces prostate cancer cells apoptosis. ChemistrySelect 2016, 1, 4658-4667.
19. Silberman, A.; Albeck, M.; Sredni, B.; Albeck, A. The ligand substitution reactions of the tellurium compound AS-101 in physiological aqueous and alcoholic solutions. Inorg Chem 2016, 55, 10847-10850.
20. Shokhen, M.; Albeck, A. How Does the Exosite of Rhomboid Protease Affect Substrate Processing and Inhibition? Prot. Sci. 2017, 26, 2355-2366.
21. Avraham, Y.; Berry, E. M.; Donskoy, M.; Vorona, L.; Albeck, A.; Mankuta, D. Beta-carotene as a novel therapy for the treatment of autistic symptoms in animal models of autism. Behav. Brain Res. 2019, 364, 469-479.
22. Nihamkin, M.; Isac, A.; Albeck, A.; Mastai, Y.; Toker, Y. Gas Phase Bond Formation in Dipeptide Clusters. J. Phys. Chem. Lett. 2020, 11, 10100-10105.
23. Ayyathan, D. M.; Levy-Cohen, G.; Shubely, M.; Boutros-Suleiman, S.; Lepechkin-Zilbermintz, V.; Shokhen, M.; Albeck, A.; Gruzman, A.; Blank, M. Development and characterization of SMURF2-targeting modifiers. J. Enz. Inhib. Med. Chem. 2021, 36, 401-409.
24. Khalfin, B.; Lichtenstein, A.; Albeck, A.; Nathan, I. Targeting necrosis: elastase-like protease inhibitors curtail necrotic cell death both in-vitro and in three in-vivo disease models. J. Med. Chem. 2021, 64, 1510-1523.
25. Avraham, Y.; Mankuta, D.; Lipsker, L.; Vorobiev, L.; Patael, S.; Hassid, G.; Berry, E. M.; Albeck, A. Beta-carotene derivatives as novel therapy for the prevention and treatment of autistic symptoms. Bioorg. Chem. 2021, 115, 105224.
26. Lerman, E.; Levinger S.; Albeck, A. Optically active functionalized building blocks for peptidyl olefin peptidomimetics. ChemistrySelect 2021, 6, 7912-7918.
